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Summary
Objective: Resistin is a secreted factor that is elevated in rheumatoid arthritis (RA) and believed to drive joint inﬂammation in vivo. This study
was undertaken to determine if resistin is present in the joint following joint injury and to elucidate the role of resistin in cartilage degradation.
Methods: The level of resistin was measured in paired synovial ﬂuid (SF) and serum samples from patients following joint injury (anterior cru-
ciate ligament, ACL or meniscus tear). Localization of resistin was visualized by immunohistochemistry of synovial tissue and cartilage from
healthy and OA donors. Mouse and human cartilage cultures were used to assess the effect of resistin on cartilage metabolism.
Results: In trauma patients, resistin levels declined with increasing time post injury. The resistin levels were highest in samples collected up to
1 week following traumatic injury (SF: 2980 pg/ml, serum: 7901 pg/ml) and lowest in samples collected 6e26 years post injury (SF: 686 pg/ml,
serum: 5682 pg/ml). Resistin was shown to be expressed in macrophage-like cells in both healthy and OA synovial tissue. Treatment of
mouse cartilage cultures with recombinant resistin led to a dose dependent loss of proteoglycan and induction of inﬂammatory cytokine
and PGE2 production. Recombinant resistin inhibited proteoglycan synthesis in human cartilage explants.
Conclusion: Resistin is elevated both systemically and locally in the weeks immediately following joint injury and has a direct effect on cartilage
matrix turnover and cytokine production. Resistin may play a role in the early stages of trauma-induced OA and may represent a new ther-
apeutic target to slow joint destruction in OA.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Abbreviations: SF synovial ﬂuid, OA osteoarthritis, RA rheumatoid arthritis, ACL anterior cruciate ligament, IL-1a interleukin 1, alpha, IL-1b
interleukin 1, beta, IL-1Ra interleukin 1 receptor antagonist, IL-6 interleukin 6, IL-7 interleukin 7, CCL4/MIP-1a chemokine (C-C motif) ligand
4, CCL3/MIP-1b chemokine (C-C motif) ligand 3, CXCL8/IL-8 interleukin 8, IL-10 interleukin 10, CCL2/MCP-1 chemokine (C-C motif) ligand 2,
G-SCF colony stimulating factor 3, TNF-a tumor necrosis factor, alpha, EGF epidermal growth factor (beta-urogastrone), GMSCF colony stim-
ulating factor 2, CCL5/Rantes chemokine (C-C motif) ligand 5, CCL11/Eotaxin chemokine (C-C motif) ligand 11, CXCL10/IP-10 chemokine
(C-X-C motif) ligand 10, IL-2 interleukin 2, IL-5 interleukin 5, IL-4 interleukin 4, TGFa transforming growth factor, alpha, CXCL1/fractalkine
chemokine (C-X3-C motif) ligand 1, IL-12p40 interleukin 12b, IL-13 interleukin 13, IL-15 interleukin 15, IL-17 interleukin 17, sCD40L CD40
ligand, VEGF vascular endothelial growth factor A, PGE2 prostaglandin E synthase 2, IFNg interferon gamma, NFkB nuclear factor of kappa
light polypeptide gene enhancer in B-cells, ESR erythrocyte sedimentation rate, IHC immunohistochemistry, CRP C-reactive protein, CXCL8/
KC mouse orthologue of human interleukin 8, CCL2/JE mouse orthologue of human chemokine (C-C motif) ligand 2, DAS28 disease activity
score 28.Introduction
Human resistin is a macrophage/monocyte-derived1 proin-
ﬂammatorymediator that belongs to the found in inﬂammatory
zone (FIZZ) protein family containing a conserved C-terminal
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613proinﬂammatory cytokines including interleukin 1 (IL-1), inter-
leukin 6 (IL-6), IL-12, and tumor necrosis factor, alpha (TNF-a)
mediated by nuclear factor of kappa light polypeptide gene
enhancer in B-cells (NFkB) 3,4. It induces the expression of in-
tracellular adhesion molecule-1, vascular cell-adhesion mole-
cule-1 and chemokine (C-C motif) ligand 2 (CCL2/MCP-1), all
of which are in chemotactic pathways involved in leukocyte
recruitment to sites of inﬂammation5e7. Resistin itself can be
up-regulated by interleukins and also by microbial antigens
such as lipopolysaccharide8.
Serum resistin levels are positively correlated with inﬂamma-
tory markers in patients with metabolic diseases9,10. Recent
studies have shown that resistin is increased in rheumatoid joint
ﬂuid4 and is associated with increased TNF-a, erythrocyte sed-
imentation rate (ESR), C-reactive protein (CRP), and disease
614 J. H. Lee et al.: Resistin is elevated following joint injuryactivity score 28 (DAS28)11,12. In contrast, one studyof 31 rheu-
matoid arthritis (RA) and 18 healthy individuals failed to detect
an increase in resistin levels in RA synovial ﬂuids (SFs)13.
Osteoarthritis (OA) is a disease of the whole joint and its
pathology is characterized by loss of hyaline articular carti-
lage, osteophyte formation, bony sclerosis, synovial inﬂam-
mation, increased laxity of the ligaments, and weakening of
the muscles surrounding the joint14. Though OA has histor-
ically been thought of as a non-inﬂammatory arthritis driven
by joint malalignment and biomechanical factors, there is in-
creasing evidence that synovial tissue inﬂammation is
a characteristic in at least a subset of cases. Synovial ab-
normalities visible during arthroscopy were reported in
50% of patients with painful primary OA with inﬂammation
of the synovial membrane visible in 21%15. Inﬂamed syno-
vium was associated with more severe cartilage degrada-
tion over 1 year15. Histologic analysis of synovial tissue
from OA patients revealed 31% with severe inﬂammation
characterized by thickened intimal lining, angiogenesis,
and macrophage inﬁltration16. Magnetic resonance imaging
(MRI) has also been used to quantify synovial thickening
and this correlates with synovial inﬂammation by histologic
analysis of biopsies in OA patients17.
Following joint injury in early adulthood, patients are at an
increased risk for the early development of OA18e21, irre-
spective of surgical intervention to stabilize the joint22,23.
In men and women who tore their anterior cruciate ligament
(ACL) in early adulthood, 41% and 51%, respectively, pro-
gressed to radiographic OA within 14 years22,23. Meniscal
tears typically occur in middle age and 43% of patients
with this type of injury progressed to OA by 16 years24. Joint
injury appears to initiate a cascade of metabolic responses
which, in some individuals, result in cartilage destruction,
pain, compromised function, and eventually OA. Analysis
of human SFs after ACL or meniscal injury has shown ele-
vated levels of cartilage matrix molecules, matrix degrading
enzymes, and inﬂammatory cytokines (interleukin 1, beta
(IL-1b), TNF-a, IL-6)25e31. Taken together, these data sug-
gest that inﬂammation is a part of OA pathology and may
contribute to disease progression.
The primary objectives of this study were (1) to assess
the levels of resistin in SF and serum of patients with in-
jury-induced OA, and (2) to elucidate the direct effects of re-
sistin on cartilage in culture. The data from such studies
may provide evidence that blocking resistin activity follow-
ing joint injury has the potential to decrease inﬂammation
and cartilage degradation and thereby slow progression of
joint deterioration toward OA in this patient population.
Materials and methodsRESISTIN LEVELS IN SERUM AND SFPaired SF and serum samples were obtained from patients at various
times following knee injury (n¼ 216). SF was obtained without lavage by joint
aspiration to dryness. Injury patients included ACL tears, meniscal tears, or
a combination of ACL and meniscus damage diagnosed by arthroscopy (me-
dian age 31 (range 13e70) years, 51/216 women). Resistin levels were as-
sayed using an adipokine multiplex kit that included adiponectin, resistin, and
active PAI-1 (Linco Research, St Charles, MO). Measurement of resistin by
this kit was validated by spike and recovery experiments. The determined
working ranges of the assay used were 2.9e1800 pg/ml and 0.6e9200 pg/
ml for serum and SF, respectively, with a recovery range of 80e120%.
The intra- and inter-assay variabilities were below 10% and 20%, respec-
tively. The serum and SF samples were measured at a dilution 1/4000 and
1/5, respectively. When the measured concentration in either matrix was
above the upper limit of quantiﬁcation, the sample was further diluted to
fall into the working range and re-measured. Results from injury patients
were split into similar size groups (n¼ 29e43) that represented different
lengths of time since injury. Summary statistics for paired serum and SF
samples were calculated and boxplots over time were created.IMMUNOHISTOCHEMISTRY (IHC) WITH ANTI-RESISTIN
ANTIBODY IN JOINT TISSUESFixed, parafﬁn embedded synovial and cartilage tissues from three
healthy and three OA patient donors were analyzed by IHC with an anti-re-
sistin antibody (R&D Systems, Minneapolis, MN). Tissues were sectioned at
4 mm, dewaxed through 4- and 5-min changes of xylene, and then re-hy-
drated by a graded alcohol series to distilled water. Steam heat induced epi-
tope recovery was used followed by 20 min blocking and 60 min primary
antibody incubation. A biotinylated secondary antibody was used for detec-
tion. Tissues were counter stained with hematoxylin. Staining with an isotype
control antibody was used to assess speciﬁcity of IHC with anti-resistin
antibody.RESISTIN TREATMENT OF MONOCYTESHuman primary monocytes isolated from three normal healthy volunteers
were purchased from AllCells, LLC (Emeryville, CA). The cells were treated
with recombinant human resistin (Peprotech, Inc, Rocky Hill, NJ; endotoxin
level was measured as 0.9 EU/mg of protein). Following 2 days of culture
in complete DMEM media containing 10% fetal bovine serum (FBS), condi-
tioned media were collected and cytokines/chemokines assayed in duplicate
by a human 30-plex cytokine kit (Linco Research, St Charles, MO). Statistical
signiﬁcance was calculated using Dunnett’s test.CARTILAGE CULTURE IN SUPERNATANTS FROM
RESISTIN-TREATED MONOCYTESFemoral head articular cartilage was isolated from 3-week old mice as de-
scribed previously32 and incubated for 2 days in DMEM with 10% FBS, an-
tibiotics, HEPES buffer (Invitrogen, Carlsbad, CA), and ascorbic acid (Sigma,
St. Louis, MO) to allow equilibration of the tissue to culture. Following this pe-
riod, cartilage was cultured in conditioned media from human monocytes
treated with recombinant human resistin (see above) diluted 1:3 with com-
plete DMEM containing 10% FBS. Following 3 days of culture, media were
collected and glycosaminoglycan (s-GAG) concentrations were measured
by a Dimethylmethylene blue (DMMB) assay. Statistical signiﬁcance was cal-
culated using Dunnett’s test.RESISTIN-TREATED CARTILAGEFemoral head articular cartilage was isolated from 3-week old mice and
cultured as described above. Following equilibration, media were changed
and varying amounts of recombinant human resistin (Peprotech, Inc, Rocky
Hill, NJ) were added to the cultures. On day three of resistin treatment,
culture media were collected and assayed for cytokines using the mouse
22-plex cytokine kit (Linco Research, St Charles, MO), prostaglandin E syn-
thase 2 (PGE2) by ELISA (R&D Systems, Minneapolis, MN), and s-GAG
content by the DMMB assay. Cartilage tissue was ﬁxed and prepared for his-
tology. Brieﬂy, 5 mm sections were deparafﬁnized, hydrated, and stained for
s-GAG content by Toluidine Blue.
Human cartilage tissue samples were procured through Asterand, plc.
(Detroit, MI). All tissues were collected pursuant to patient authorization reg-
ulated by the U.S. Health Insurance Portability & Accountability Act (HIPAA)
and under approval of the Supplier’s IRB and in accordance with all Centocor
and Johnson & Johnson policies for ethical use and safety. Tissues were re-
ceived within 24 h post mortem. Full thickness, 3 mm diameter biopsy
punches were taken from femoral condyle cartilage of two non-OA donors
and washed in PBS with antibiotics. These explants were then placed in
50:50 low glucose DMEM:F12 base media supplemented with 10% FBS,
1% antibiotic/antimycotic, 1% HEPES and 2% ascorbic acid and cultured
at 37 C in a humidiﬁed incubator with 5% CO2 and allowed to equilibrate
for 72 h. Following equilibration the explants were treated with recombinant
resistin for 14 days (media change containing fresh resistin was added every
3e4 days). Cultured media were collected every 3e4 days during the treat-
ment period and the concentration of s-GAG released was measured by
DMMB assay. To assess proteoglycan synthesis the explants were incu-
bated with [35S]-sodium sulfate (PerkinElmer, Waltham, MS) for 16 h on
the last treatment day. After labeling, the explants were washed in four
changes of phosphate buffer and then digested with proteinase K (Roche,
Mannheim, Germany). The [35S]-sulfate content of the digests was then
counted on scintillation counter. Statistical signiﬁcance was calculated using
Dunnett’s test.
ResultsRESISTIN LEVELS IN SERUM AND SFResistin protein was detected in all serum and synovial
ﬂuid samples tested. The level of resistin in both SF and
615Osteoarthritis and Cartilage Vol. 17, No. 5serum was high after meniscal and ligament injury and
declined with increasing time post injury. In SF, the major-
ity of resistin values> 50,000 pg/mL were observed from
1 day to 10 weeks after injury. In serum, the highest
values (>25,000 pg/mL) were distributed over a longer
period post injury, one-third of these values were still ob-
served in samples collected within 3 weeks of injury. TheFig. 1. Resistin levels in SF (A) and serum (B) samples from patients tak
were chosen to produce an approximately equal number of samples in e
and whiskers plots where the line across the middle of the box is the medi
kers’’ extending above and below the box end at the most extreme data p
the ends of the box. Any data points beyond this are displayed as circles.
shorter time points e up tomedian resistin level in SF dropped from w2980 pg/ml in
samples collected up to 1 week after injury to w686 pg/ml
in samples collected 6e26 years post injury (an approxi-
mately fourfold decrease) [Fig. 1(A)]. Median serum resis-
tin level changed from w7901 pg/ml immediately after
injury to w5682 pg/ml in samples collected 6e26 years
post injury [Fig. 1(B)].en at different times since posttraumatic joint injury. Time intervals
ach group (n¼ 29e43 in each interval). The data presented in box
an, the limits of the box are the 25th and 75th percentiles The ‘‘whis-
oint that is no more than 1.5 times the interquartile range away from
The highest resistin values in both SF and serum were observed at
5 weeks after injury.
Fig. 2. IHC staining of synovium (A, B) and cartilage (C, D) tissues from normal (A, C) and OA (B, D) patients with an anti-resistin antibody. The
arrows indicate examples of the cells positively stained with anti-resistin antibody. Magniﬁcation is 40. The images are representative of
sections taken from three patients.
Table I
Human primary monocytes isolated from two healthy donors were treated for 48 h with and without recombinant human resistin
(10 mg/ml). Cytokines/chemokines released from monocytes were assayed with a human 30-plex cytokine kit. Results are presented as mean
(pg/ml)  SD
Cytokine Donor 1 Donor 2
Untreated Resistin Untreated Resistin
IL-1a N/D 415 2010 60110
IL-1b 2810 12012 49310 311617
IL-1Ra 2776 580412 78315 16,31820
IL-6 173820 11,89510 22555 14,47920
IL-7 4.62 253 123 509
CCL4/MIP-1a 11010 36028 33142 311815
CCL3/MIP-1b 2266 112310 79315 618520
CXCL8/IL-8 502114 29,47050 80962 47,42160
IL-10 2107 204615 41413 449110
CCL2/MCP-1 223710 13,94320 6076 10,63030
G-SCF 1763 10258 35928 341311
TNF-a 429 27310 6820 5767
EGF N/D 172 N/D 264
GMSCF N/D N/D N/D 225
CCL5/Rantes N/D N/D N/D 525
CCL11/Eotaxin N/D N/D N/D N/D
CXCL10/IP-10 N/D N/D N/D N/D
IL-2 N/D N/D N/D N/D
IL-5 N/D N/D N/D N/D
IL-4 N/D N/D N/D N/D
TGFa N/D N/D N/D N/D
CX3CL1/fractalkine N/D N/D N/D N/D
IL-12p70 N/D N/D N/D N/D
IL-12p40 N/D N/D N/D N/D
IL-13 N/D N/D N/D N/D
IL-15 N/D N/D N/D N/D
IL-17 N/D N/D N/D N/D
sCD40L N/D N/D N/D N/D
VEGF N/D N/D N/D N/D
IFNg N/D N/D N/D N/D
N/D e below the limit of detection.
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lPositive staining with an anti-resistin antibody was de-
tected in 3/3 normal and OA synovial tissue samples
tested. The cell types stained with an anti-resistin antibody
were predominantly macrophages and mast cells evenly
distributed within the synovium [Fig. 2(A, B)]. Immunoreac-
tive macrophages and mast cells appeared to be more nu-
merous in OA synovium compared to synovium tissue
samples from normal donors that might be due to an
increase in joint inﬂammation often observed in OA
patients15e17. Cartilage was negative for resistin staining
in 3/3 tested samples from healthy and OA donors
[Fig. 2(C, D)]. No staining with the isotype control antibody
was detected (data not shown).B
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lRecombinant human resistin induced the release of
multiple cytokines and chemokines from primary mono-
cytes isolated from the blood of healthy donors. The high-
est concentration (10 mg/ml) of resistin stimulated the
secretion of 13 cytokines out of 30 tested (Table I). IL-6,
interleukin 8 (CXCL8/IL-8) and CCL2/MCP-1 were among
the cytokines whose secretion was highly increased in
a dose dependent manner upon resistin treatment
[Fig. 3(AeC)].0 0.1 1 5 10
0
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lTo assess if cytokines released by resistin from immuno-
competent cells affect cartilage degradation, mouse carti-
lage explants were incubated with the conditioned media
from monocytes treated with recombinant human resistin.
The conditioned media from resistin-treated monocytes
caused the release of proteoglycans from the tissue into
the culture media (Fig. 4). This effect was dose dependent;
increasing resistin concentrations on immunocompetent
cells resulted in increased levels of proteoglycan release
from cartilage.*
*
C
CRESISTIN-TREATED CARTILAGE0 0.1 1 5 10
0
Resistin, µg/ml
Fig. 3. Human monocytes from two donors were treated with
recombinant human resistin for 48 h and resistin-stimulated (A)
IL-6, (B) CXCL8/IL-8 and (C) CCL2/MCP-1 release were assayed
by human multiplex cytokine kit. Each sample was run in duplicate.
Results are presented as mean (pg/ml) SD, * indicates P-value
< 0.05 by Dunnett’s test.We next sought to determine the direct effects of resistin
on cartilage explant cultures. Resistin treatment led to re-
lease of s-GAG from the cartilage extracellular matrix to
the medium [Fig. 5(A)] and decreased proteoglycan staining
intensity with Toluidine Blue from the periphery of the
mouse cartilage explants [Fig. 5(BeE)]. In addition, mouse
cartilage explants treated with resistin released increased
levels of IL-6, CXCL8/KC (mouse orthologue of human in-
terleukin 8) and CCL2/JE (mouse orthologue of human che-
mokine (C-C motif) ligand 2) compared to untreated control
cultures [Fig. 6(A)]. Other cytokines and chemokines were
below the level of detection in conditioned media from resis-
tin-treated mouse cartilage. In addition, resistin caused
a dose dependent increase in the release of a proinﬂamma-
tory molecule, PGE2, from mouse cartilage explants
[Fig. 6(B)].
To determine the effect of resistin on mature articular car-
tilage, human cartilage explants were isolated from two
non-OA donors and treated with recombinant resistin. In
contrast to mouse femoral head cultures, resistin did not
signiﬁcantly affect proteoglycan release in human explants
(data not shown) within the culture period studied. This
might be explained by higher resistance of adult cartilageto proteoglycan degradation compared to relatively young
cartilage isolated from 3-week old mice. However, both con-
centrations of resistin (1 and 10 mg/ml) signiﬁcantly inhibited
proteoglycan synthesis as assessed by [35S]-sulfate incor-
poration (Fig. 7).
Discussion
Over the past decade the role of inﬂammation in the path-
ogenesis of OA has received increased attention. As a result
there is now increasing evidence that, at least in a subset of
patients, the inﬂammatory cascade may be a prevalent
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Fig. 4. Mouse articular cartilage was cultured in conditioned media
from resistin-treated monocytes. An increase in the release of
s-GAG was measured in the media following 3 days of culture using
the DMMB assay. Results are presented as mean SE, n¼ 4;
* indicates P-value< 0.05 by Dunnett’s test.
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Fig. 5. Mouse articular cartilage was treated with human recombi-
nant resistin for 3 days. (A) Culture supernatants were assayed
for s-GAG content by the DMMB dye assay. Results presented
are meanSE, n¼ 4; * indicates P-value< 0.05 in individual pair-
wise comparisons of each active group vs the control using Dun-
nett’s test. Control (B, D) and 10 mg/ml resistin-treated (C, E)
cartilage explants were ﬁxed for histology and stained with Tolui-
dine Blue to visualize loss of proteoglycans. Magniﬁcation is 10
(B, C) and 40 (D, E). The arrows indicate decreased staining in-
tensity of the cartilage matrix in the periphery of the tissue explants.
618 J. H. Lee et al.: Resistin is elevated following joint injurycause of articular cartilage loss. The studies presented here
implicate the involvement of a recently described pro-
inﬂammatory cytokine, resitin, in the pathogenesis of OA.
Resistin was originally identiﬁed in mice as an adipokine
that might provide the link between obesity and insulin re-
sistance33. This idea primarily stems from studies demon-
strating that serum resistin levels increase with obesity in
mice, rats and humans34e37. Since these observations,
the physiologic role of resistin and its involvement in insulin
resistance and diabetes have been the subject of much
controversy. It is worth noting that the resistin receptor
has not been identiﬁed and that the signaling pathways
are not well understood, adding further layers of complexity
for understanding resistin biology. Recent research shows
that human resistin is expressed in immune cells1 and
possesses many characteristics of a proinﬂammatory
cytokine4e7. Senolt et al. implicated resistin in the develop-
ment of RA based on the positive correlation of disease pro-
gression with resistin serum and SF levels in RA patients12.
Injection of recombinant resistin into the healthy mouse
knee results in inﬂammatory arthritis in the injected joint4 in-
dicating a potential role for resistin in driving joint inﬂamma-
tion. Resistin association with obesity together with its
proinﬂammatory proﬁle suggest that resistin might be one
of the mediators that links OA with inﬂammation and
obesity.
We establish for the ﬁrst time a direct role for resistin in
cartilage matrix turnover, and in the induction of
inﬂammatory cytokines and PGE2 secretion from cartilage
cultures. Recombinant resistin stimulated proteoglycan
degradation in mouse femoral head cultures and inhibited
proteoglycan biosynthesis in human cartilage. Furthermore,
we show that resistin is elevated in both serum and SF
shortly after joint injury, a period that is often associated
with enhanced joint inﬂammation25e31. Increased systemic
and local resistin levels following injury, together with its ef-
fect on cartilage matrix turnover favoring breakdown over
synthesis, suggest that resistin may be involved in the early
stages of OA and could be a novel target for the treatment
of injury-induced OA.
Resistin is expressed in monocytes/macrophages2 and
we further demonstrate that it can act in a paracrine mannerto evoke inﬂammatory responses from primary monocytes.
Cytokines secreted by monocytes in response to resistin
drive cartilage matrix breakdown. We demonstrate that, in
addition to its direct effect, resistin also indirectly affects car-
tilage matrix degradation through cytokines released from
immune cells. Other inﬂammatory cytokines, such as
TNF-a and IL-1, drive disease activity in RA and are consid-
ered to be promising targets in OA38e40. These cytokines
have a similar ability to modulate inﬂammation and cartilage
breakdown both directly and indirectly.
As was previously shown for primary OA12,41, serum
levels of resistin are higher than in paired SF samples fol-
lowing joint injury. Of interest here is that the median ratio
of SF to serum resistin for individual patients was 0.31 dur-
ing the ﬁrst weeks following injury and gradually decreased
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Fig. 6. Mouse cartilage explants were treated with different concentrations of recombinant human resistin for 3 days. Resistin-stimulated secre-
tion of IL-6, CCL2/JE, CXCL8/KC (A) and (B) PGE2 was measured by Luminex or ELISA kit, respectively. Results presented are meanSE,
n¼ 4; * indicates P-value< 0.05 in individual pairwise comparisons of each active group vs the control using Dunnett’s test.
619Osteoarthritis and Cartilage Vol. 17, No. 5to 0.15 in samples collected 6e26 years following injury.
A post injury increase in the ratio of local to systemic levels
suggests that resistin might accumulate in the joint from the
circulation or alternatively local resistin production in the
joint tissues might be up-regulated following an injury event.
In agreement with a previous study41, we detected resistin
immunostaining in macrophage-like cells in normal and
OA synovial tissues. We speculate that macrophage-like
cells resident in the synovium might contribute to an in-
crease in the local concentration of resistin in joints. Given
their immune nature, these cells could be attracted to the
joints and/or become activated in inﬂammatory conditions
induced by injury. Although Presle et al. did not detect resis-
tin in culture supernatants of joint tissues obtained at arthro-
plasty (cartilage, synovium, fat pad, meniscus, osteophyte,
and bone), high levels of resistin were measured in homog-
enates of synovium and fat pad obtained from OA joints41.
Further investigation is required to understand what stimu-
lus might trigger resistin release from synovial tissue.0 1 10
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Fig. 7. Humanarticular cartilage explants isolated froma non-OAdo-
nor were treated with recombinant human resistin for 14 days. Pro-
teoglycan synthesis was measured by [35S]-sulfate incorporation
during the last 16 h of treatment. The explants isolated froma second
non-OA donor showed similar inhibition in proteoglycan synthesis in
response to resistin treatment. Results presented are mean SE,
n¼ 6; * indicates P-value< 0.05 in individual pairwise comparisons
of each active group vs the control using Dunnett’s test.Our study is limited by the cross sectional nature of the clin-
ical samples analyzed for resistin, and by lack of information
on bodymass index of the patients. Body ﬂuid levels of many
biomarkers, in particular those in serum, have been shown to
change with age, body mass index and disease stage of OA.
Resistin levels were not corrected for these confounders. To
further understand how resistin levels change in injury pa-
tients over time, analysis of longitudinal samples is needed.
To understand the role of resistin in human disease, studies
with human cartilage at various disease stages and from dif-
ferent patient populations are required.
Intra-articular injection of resistin into healthy mouse
joints caused inﬂammatory arthritis within 4 days character-
ized by synovitis, pannus formation, and cartilage destruc-
tion4. Our study further emphasizes the inﬂammatory
nature of resistin as it triggers cytokine release not only
from immune cells but also from cartilage explants. Inﬂam-
matory responses mediated by resistin directly from chon-
drocytes and/or from other cells present in femoral head
explants, in turn, affect extracellular matrix metabolism
and contribute to cartilage tissue destruction. The next
step for in vivo analysis will be to determine if speciﬁc inhib-
itors of resistin are able to slow or prevent inﬂammatory or
injury induced joint degradation.
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